CONCLUSIONS At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight m and atory domains of the PsA COS
BACKGROUND An up date d psoriatic arthritis ( PsA ) core outcome set ( COS ) for r and omized controlled trials ( RCTs ) was endorsed at the Outcome Measures in Rheumatology ( OMERACT ) meeting in 2016 .
OBJECTIVES To synthesize the evidence on measurement properties of patient reported outcome measures ( PROMs ) for PsA and thereby contribute to development of a PsA core outcome measurement set ( COMS ) as described by the OMERACT Filter 2.0 .
Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity
Background : The objective of this study was to evaluate the measurement properties of the Psoriasis Symptom Inventory ( PSI ) , an eight-item patient-reported outcome measure for assessing severity of plaque psoriasis symptoms . Methods : In this prospect i ve , r and omized study using data from adults with moderate-to-severe plaque psoriasis , patients completed the PSI , Dermatology Life Quality Index ( DLQI ) , SF-36v2 Acute , and Patient Global Assessment ( PtGA ) . PSI construct validity was assessed using Spearman rank correlations between PSI and DLQI and SF-36 ; test-retest reliability and sensitivity to change were evaluated using PtGA as an anchor . Daily 24-h and weekly 7-day PSI versions were evaluated . Results : Eight US sites enrolled 143 patients ; 139 ( 97.2 % ) completed the study . All symptoms ( itch , redness , scaling , burning , cracking , stinging , flaking , and pain ) were reported across all response options ( not at all severe , mild , moderate , severe , very severe ) . Test-retest reliability was acceptable ( intraclass correlation coefficients range = 0.70–0.80 ) . A priori hypotheses of convergent and discriminant validity were confirmed by correlations of PSI with DLQI items and SF-36 domains . The PSI demonstrated good construct validity and was sensitive to within-subject change ( p < 0.0001 ) . Conclusions : The PSI is brief , valid , reproducible , and responsive to change and has the potential to be a useful PRO measure in psoriasis clinical trials
CONCLUSIONS At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight m and atory domains of the PsA COS
BACKGROUND An up date d psoriatic arthritis ( PsA ) core outcome set ( COS ) for r and omized controlled trials ( RCTs ) was endorsed at the Outcome Measures in Rheumatology ( OMERACT ) meeting in 2016 .
OBJECTIVES To synthesize the evidence on measurement properties of patient reported outcome measures ( PROMs ) for PsA and thereby contribute to development of a PsA core outcome measurement set ( COMS ) as described by the OMERACT Filter 2.0 .